[1] 何静, 程义壮, 刘学公, 等.云克治疗Graves眼病的护理方法[J].安徽医学, 2015, 36(2):225.
[2] 屠晓芳, 张洪梅.甲状腺相关性眼病的评估方法及激素治疗进展[J].中国全科医学, 2017, 20(18):2294.
[3] SCOTT DW, WRIGHT GW, WILLIAMS PM, et al.Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue[J]. Blood, 2015, 123(8):1214.
[4] 刘观鑫.云克联合甲基强的松龙冲击治疗甲状腺相关眼病的临床观察[J].医学信息, 2015, 28(8):96.
[5] MACMILLAN ML, AUERBACH AD, DAVIES SM, et al.Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors:results of a total body irradiation dose escalation trial[J]. British J Haematol, 2015, 109(1):121.
[6] LIU Z, ZHANG H, LIU Z, et al.Multitarget therapy for induction treatment of lupus nephritis:a randomized trial[J]. Ann Int Med, 2015, 162(1):18. doi: 10.7326/M14-1030
[7] 王秀生, 李国良, 王强, 等.云克联合雷公藤多甙治疗甲状腺相关眼病临床研究[J].中国实用眼科杂志, 2009, 27(12):1369.
[8] CHENG AL, YEH KH, UEN WC, et al.Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma:a pilot study of the BOMES protocol[J]. Cancer, 2015, 82(10):1946.
[9] 唐真武, 姜俊, 黄江河, 等.99锝-亚甲基二膦酸盐三联法治疗甲状腺相关性眼病临床分析[J].中华实用诊断与治疗杂志, 2013, 27(2):201.
[10] RAYMOND E, TRICOTTET V, SAMUEL D, et al.Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation[J]. Cancer, 2015, 76(8):1344.
[11] RATHI M, GOYAL A, JARYAL A, et al.Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis[J]. Kidney Int, 2016, 89(1):235. doi: 10.1038/ki.2015.318
[12] 99锝-亚甲基二膦酸盐联合甲泼尼龙治疗甲状腺相关眼病疗效分析[J].第二军医大学学报, 2012, 33(7): 808.
[13] FERVENZA FC, CANETTA PA, BARBOUR SJ, et al.A multicenter randomized controlled trial of Rituximab versus Cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)[J]. Nephron, 2015, 130(3):159. doi: 10.1159/000430849
[14] TSELIOS K, SARANTOPOULOS A, GKOUGKOURELAS I, et al.The influence of therapy on CD4+CD25(high)FOXP3+ regulatory T cells in systemic lupus erythematosus patients:a prospective study[J]. Scand J Rheumatol, 2015, 44(1):29. doi: 10.3109/03009742.2014.922214
[15] MOUNIER N, MOREL P, HAIOUN C, et al.A multivariate analysis of the survival of patients with aggressive lymphoma:variations in the predictive value of prognostic factors during the course of the disease.Groupe d'Etudes des Lymphomes de l'Adulte[J]. Cancer, 2015, 82(10):1952.